Journal of the American College of Cardiology Vol. 49, No. 6, by the American College of Cardiology Foundation ISSN /07/$32.
|
|
- Francis Stevens
- 5 years ago
- Views:
Transcription
1 Journal of the American College of Cardiology Vol. 49, No. 6, by the American College of Cardiology Foundation ISSN /07/$32.00 Published by Elsevier Inc. doi: /j.jacc Myocardial Infarction Effects of Intravenous Atrial Natriuretic Peptide on Cardiac Sympathetic Nerve Activity and Left Ventricular Remodeling in Patients With First Anterior Acute Myocardial Infarction Shu Kasama, MD,* Takuji Toyama, MD,* Takashi Hatori, MD,* Hiroyuki Sumino, MD,* Hisao Kumakura, MD, Yoshiaki Takayama, MD, Shuichi Ichikawa, MD, Tadashi Suzuki, MD,* Masahiko Kurabayashi, MD* Maebashi and Gunma, Japan Objectives Background Methods Results We sought to evaluate the effects of atrial natriuretic peptide (ANP) on cardiac sympathetic nerve activity (CSNA) and left ventricular (LV) remodeling in patients with first anterior acute myocardial infarction (AMI) after primary coronary angioplasty. The activation of the renin-angiotensin-aldosterone system (RAAS) prevents the uptake of norepinephrine in the myocardium. Atrial natriuretic peptide, a circulating hormone of cardiac origin, has vasodilatory and diuretic properties, and can inhibit the RAAS. We studied 50 patients with first anterior AMI who were randomly assigned to receive ANP (group A) or isosorbide dinitrate (group B) before and after primary coronary angioplasty. The ANP or ISDN was continuously infused 48 h. The extent score (ES) was determined from 99m Tc-pyrophosphate scintigraphy to evaluate the area of initial myocardial damage 3 to 5 days after primary angioplasty. The LV end-diastolic volume (LVEDV) and LV ejection fraction (LVEF) were determined by left ventriculography 2 weeks later. The delayed heart/mediastinum count (H/M) ratio, delayed total defect score (TDS), and washout rate (WR) were determined from 123 I-metaiodobenzylguanidine scintigraphy after 3 weeks. After primary angioplasty, age, gender, risk factors, peak serum creatine phosphokinase concentration, recanalization time, and ES were similar in the 2 groups. However, in group A (n 25), the TDS was significantly lower (34 8 vs. 41 8; p 0.05), the H/M ratio was significantly higher ( vs ; p 0.05), and the WR was significantly lower (35 8% vs %; p 0.005) than in group B (n 25). Moreover, the LVEDV and LVEF in group A were better than in group B (LVEDV: ml vs ml [p 0.05]; LVEF: % vs % [p 0.05]). Conclusions Intravenous ANP improves CSNA and prevents LV remodeling in patients with first anterior AMI. (J Am Coll Cardiol 2007;49:667 74) 2007 by the American College of Cardiology Foundation Event-free survival after acute myocardial infarction (AMI) is influenced by the extent of residual myocardial ischemia (1) and the global left ventricular (LV) ejection fraction (LVEF) (2). Patients with LV dysfunction are more likely to have progressive LV dilation, which is an independent determinant of long-term survival (3). Moreover, activation of the sympathetic nervous system is one of the cardinal From the *Department of Cardiovascular Medicine, Gunma University School of Medicine, Maebashi, Japan; and the Department of Internal Medicine, Cardiovascular Hospital of Central Japan, Gunma, Japan. Manuscript received April 24, 2006; revised manuscript received August 22, 2006, accepted September 18, pathophysiologic abnormalities associated with the failing human heart (4). Therefore, plasma norepinephrine concentrations affect the morbidity and mortality in patients with AMI (5). In the acute phase of AMI, nitroglycerin has been reported to have a favorable effect in preventing LV remodeling (6). However, this agent may stimulate the reninangiotensin-aldosterone system (RAAS) despite its beneficial hemodynamic effect (7). In contrast, atrial natriuretic peptide (ANP) has a wide range of potent biologic effects, including natriuretic, diuretic, and vasodilatory properties and inhibition of the RAAS (8). The efficacy of intravenous administration of ANP in patients with acute myocardial
2 668 Kasama et al. JACC Vol. 49, No. 6, 2007 ANP and Cardiac Sympathetic Nerve Activity February 13, 2007: Abbreviations and Acronyms 123 I-MIBG 123 I-meta-iodobenzylguanidine 99m Tc-PYP 99m Tc-pyrophosphate AMI acute myocardial infarction ANP atrial natriuretic peptide ES extent score H/M heart/mediastinum count ISDN isosorbide dinitrate LV left ventricular LVEDP left ventricular end-diastolic pressure LVEDV left ventricular end-diastolic volume LVEF left ventricular ejection fraction TDS total defect score WR washout rate infarction has been reported previously (9). In that report, the intravenous administration of ANP prevented LV dilation and remodeling after primary coronary angioplasty in patients with AMI. Myocardial imaging with 123 I- meta-iodobenzylguanidine ( 123 I- MIBG), an analog of norepinephrine, is useful for detecting abnormalities in the myocardial adrenergic nervous system in patients with AMI (10). Myocardial ischemic area and cardiac 123 I-MIBG defect size are correlated in patients undergoing reperfusion therapy for acute coronary syndromes (11). Many reports have suggested that inhibition of the RAAS can improve cardiac sympathetic nerve activity, based on cardiac 123 I-MIBG scintigraphic studies, in patients with heart disease (12 20). However, no reports discuss the changes in cardiac 123 I-MIBG scintigraphic findings in response to ANP administration in patients with AMI, although we previously reported improved cardiac sympathetic nerve activity (CSNA) in patients with nonischemic decompensated acute heart failure (17). Methods Patients. From April 2003 through February 2006, 66 patients who were admitted to the Coronary Care Unit (CCU) of our institution for their first myocardial infarction of the anterior wall and showed Thrombolysis In Myocardial Infarction (TIMI) flow grade 0 or 1 (21) at initial coronary angiography were considered as the study population. The diagnosis of AMI was made on the basis of chest pain of 30 min duration, ST-segment elevation of 2mm in 2 contiguous electrocardiographic (ECG) leads and more than threefold increase in serum creatine phosphokinase activities. Patients were excluded from the study for the following reasons: cardiogenic shock or hypotension, defined as systolic blood pressure 80 mm Hg (3 patients were excluded); prior myocardial infarction (4 patients); multivessel disease (5 patients); and need for mechanical support (intra-aortic balloon pumping, mechanical ventilation, or both) (4 patients). Therefore, this report is based on the remaining 50 patients. All patients underwent percutaneous coronary intervention (PCI) and achieved successful coronary reflow (TIMI flow grade 2 or 3) within 6 hours after the symptom onset. The study was approved by the ethics review board of our institution, and informed written consent was obtained from all patients. Study protocol. This is a prospective randomized study (double-blind, 1:1 ratio). After establishing a diagnosis of AMI, we randomly assigned the patients to receive either ANP (group A; n 25) or isosorbide dinitrate (ISDN) (group B; n 25). After the patient arrived in the CCU and hemodynamic stability was assured, ANP was continuously infused at g/kg/min in group A, and ISDN was continuously infused at 0.67 g/kg/min in group B. After the start of ANP or ISDN continuous infusions, all patients underwent cardiac catheterization with the femoral approach after an injection of 100 U/kg of heparin. The infarct-related artery was visualized in five views with contrast injections, and patency was determined according to the TIMI classification. Patients who had persistent occlusion of the infarct-related vessel (TIMI flow grade 0 or 1) underwent PCI standard techniques. Data on additional electrocardiographic ST-segment elevation and reperfusion arrhythmias were collected at the time of reperfusion. The following arrhythmias not observed before reperfusion were regarded as reperfusion arrhythmias: accelerated idioventricular or atrioventricular junctional rhythms, ventricular tachycardia (at least 3 consecutive beats), and ventricular fibrillation. After angioplasty, ANP or ISDN was continuously infused 48 h. All patients received oral aspirin and ticlopidine. Moreover, oral angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-adrenergic blocking agents, and/or diuretics were added and continued. We performed resting 201 Tl and 99m Tc-pyrophosphate (PYP) dual single-photon emission computed tomography (SPECT) imaging to evaluate the area of initial myocardial damage 3 to 5 days after primary angioplasty. Follow-up coronary angiography and left ventriculography (right anterior oblique 30 ) were performed 2 weeks after angioplasty. At our institution, follow-up catheterization is routinely performed 2 weeks after angioplasty in patients with AMI. Left ventricular end-diastolic pressure (LVEDP) was determined from a transducer connected to a pig-tail catheter just before left ventriculography. The left ventricular enddiastolic volume (LVEDV) and LVEF were calculated by the area-length method. These measurements were performed by an independent observer in a blinded manner. The 123 I-MIBG scintigraphy was performed 3 weeks later. Cardiac 123 I-MIBG scintigraphy. The method of 123 I- MIBG imaging has been described previously (14 20). Briefly, the 123 I-MIBG was obtained from a commercial source (Daiichi Radioisotope Laboratories, Tokyo, Japan). At 15 min and at 4 h after injection, the anterior planar and SPECT images were obtained with a single-head gamma camera (Millennium MPR, GE Medical Systems, Waukesha, Wisconsin). The heart/mediastinum count (H/M) ratio was determined from the anterior planar delayed 123 I-MIBG image. The washout rate (WR) was calculated from early and delayed planar images. Regional tracer uptake was assessed semiquantitatively using a 5-point scoring system
3 JACC Vol. 49, No. 6, 2007 February 13, 2007: Kasama et al. ANP and Cardiac Sympathetic Nerve Activity 669 (0 normal to 4 no uptake) in 17 segments of delayed SPECT image, as recommended by the American Heart Association (22). The total defect score (TDS) was calculated as the sum of all defect scores. Resting 201 Tl and 99m Tc-PYP dual SPECT. The method of 201 Tl and 99m Tc-PYP dual SPECT has been described previously (23). In brief, each patient received 740 MBq of 99m Tc-PYP intravenously and then 74 MBq of 201 Tl2h later. Fifteen minutes after the 201 Tl injection, all patients underwent myocardial imaging with dual SPECT with the same system. For each patient, these images were divided into 17 segments by the same method used for 123 I-MIBG imaging. We evaluated the myocardial perfusion SPECT abnormalities of 201 Tl by using the TDS calculated by the same method. Furthermore, the extent score (ES) was determined from 99m Tc-PYP as the sum of the area of abnormal uptake for all 17 segments. Statistical analysis. Statistical analysis was performed by using SPSS 12.0 for Windows (SPSS Inc., Chicago, Illinois). Numerical results are expressed as mean SD. Comparison of baseline categoric data between the 2 groups was done by the chi-square test, and differences between continuous variables were evaluated using the unpaired t test. The reperfusion phenomenon of additional electrocardiographic ST-segment elevation and reperfusion arrhythmias were expressed as percentages and compared by Fisher exact test. A value of p 0.05 was considered to be statistically significant. Results Clinical characteristics. No significant differences were observed in clinical characteristics between the subjects in the 2 groups on entry into the study. Age, gender, recanalization time, and peak creatine phosphokinase levels in the acute phase were similar for both groups (Table 1). The mean duration of ANP administration was h (range 48 to 96 h) in group A, and that of ISDN administration was h (range 48 to 96 h) in group B. There were also no differences in the in-hospital medications between the 2 groups. The mean dose of enalapril was mg/day in group A versus mg/day in group B (p NS). The mean dose of perindopril was mg/day in group A versus mg/day in group B(p NS). The mean dose of valsartan was mg/day in group A versus mg/day in group B (p NS). The mean dose of carvedilol was 12 5 mg/day in group A versus 11 4 mg/day in group B (p NS). The mean dose of furosemide was mg/day in group A versus mg/day in group B (p NS). Finally, the dose of spironolactone was only 25 mg/day in both groups. Other in-hospital therapies and clinical follow-up were similar in both groups. Comparison of reperfusion phenomenon. The incidence of additional electrocardiographic ST-segment elevation in group A was significantly lower than in group B (20% vs. Clinical Parameters Characteristics of Patients in and Both LV Groups Table 1 Clinical Characteristics and LV Parameters of Patients in Both Groups Group A (n 25) Group B (n 25) p Value Age (yrs) Gender Male 20 (80.0%) 19 (76.0%) 0.73 Female 5 (20.0%) 6 (24.0%) 0.73 History of stroke 2 (8.0%) 1 (4.0%) 0.55 Diabetes mellitus 7 (28.0%) 6 (24.0%) 0.74 Hypertension 14 (56.0%) 13 (52.0%) 0.77 Hyperlipidemia 8 (32.0%) 9 (36.0%) 0.77 Current smoker 14 (56.0%) 15 (60.0%) 0.77 Recanalization time (h) TIMI flow grade 3 23 (92.0%) 23 (92.0%) 1.00 TIMI flow grade 2 2 (8.0%) 2 (8.0%) 1.00 Stent 23 (92.0%) 22 (88.0%) 0.64 Peak CPK (IU/l) 2,959 1,648 3,187 1, In-hospital medications ACE inhibitor 23 (92.0%) 23 (92.0%) 1.00 ARB 5 (20.0%) 6 (24.0%) 0.73 Beta-blocker 21 (84.0%) 22 (88.0%) 0.68 Loop diuretics 5 (20.0%) 6 (20.0%) 0.73 Spironolactone 2 (8.0%) 2 (8.0%) 1.00 Extent score of 99m Tc-PYP Total defect score of T LVEDP (mm Hg) LVEDV (ml) LVEF (%) Data are presented as the mean value SD. ACE angiotensin-converting enzyme; ARB angiotensin receptor blocker; CPK creatine phosphokinase; LVEDP left ventricular end-diastolic pressure; LVEDV left ventricular enddiastolic volume; LVEF left ventricular ejection fraction; TIMI Thrombolysis In Myocardial Infarction; 99m Tc-PYP 99m Tc-pyrophosphate. 35%; p 0.05), and that of reperfusion arrhythmias in group A was also lower than in group B (28% vs. 48%; p 0.05). Comparison of cardiac 201 Tl and 99m Tc-PYP dual SPECT. Table 1 provides a summary of the ES and TDS data for both groups as evaluated by cardiac 201 Tl and 99m Tc-PYP dual SPECT. From this dual SPECT, we confirmed that all patients had first anterior AMI, and there were no patients with prior myocardial infarction. The ES evaluated from 99m Tc-PYP was similar in both groups. However, the TDS of 201 Tl in group A was significantly lower than in group B (p 0.01). Comparison of left ventricular parameters 2 weeks after treatment. Table 1 presents a summary of LVEDP, LVEDV, and LVEF determined during heart catheterization. Two weeks after treatment, LVEDV was significantly lower and LVEF was significantly higher in group A than in group B (both: p 0.05). However, LVEDP was similar in both groups. Comparison of cardiac 123 I-MIBG scintigraphic findings 3 weeks after treatment. The TDS, H/M ratio, and WR are shown in Figure 1. The TDS in group A was significantly lower than in group B (p 0.05). The H/M ratio in group A was significantly higher than in group B (p
4 670 Kasama et al. JACC Vol. 49, No. 6, 2007 ANP and Cardiac Sympathetic Nerve Activity February 13, 2007: Figure 1 Comparison of Cardiac 123 I-Meta-Iodobenzylguanidine Scintigraphic Findings 3 Weeks After Treatment H/M heart/mediastinum count; TDS total defect score; WR washout rate. *p 0.05 compared with group A; p compared with group A. 0.05). Finally, the WR in group A was significantly lower than in group B (p 0.005). Representative 123 I-MIBG images for both groups 3 weeks after reperfusion therapy are shown in Figures 2 and 3. Discussion Our findings demonstrate for the first time that intravenous administration of ANP could improve cardiac sympathetic nerve activity and prevent left ventricular remodeling to a larger extent compared with ISDN after reperfusion therapy in patients with first anterior AMI. Reperfusion of the ischemic myocardium by PCI reduces the size of the infarct and improves LV function, both of which contribute to an improved clinical outcome for patients with AMI (24,25). However, in some patients who undergo reperfusion therapy, reperfusion per se adversely leads to tissue damage known as reperfusion injury (26). Intravenous administration of ANP is a promising candidate for an adjunctive therapy for AMI, because it can suppress the RAAS and endothelin-1, both of which modulate cardiac remodeling (9,27). On the other hand, ischemic preconditioning is a phenomenon in which brief periods of ischemia confer cardioprotective effects against prolonged ischemia (28). Gross and Auchampach (29) reported that ischemic preconditioning produces cardioprotection via activation of adenosine triphosphate (ATP)- sensitive potassium channels. Pharmacologic opening of the channel mimics ischemic preconditioning, whereas closing the channel blocks cardioprotection (30). Atrial natriuretic peptide is a known ATP-sensitive potassium channel activator (30); therefore, this agent may have ischemic preconditioning effect during ischemia reperfusion. Moreover, Das et al. (31) have discussed that an ATP-sensitive potassium channel activator exhibits cardioprotective effects against reperfusion injury in the myocardium. In that report, selective activation of mitochondrial ATP-sensitive potassium channels increased survival rate and decreased the incidence of arrhythmias. In the present study, the incidence of additional electrocardiographic ST-segment elevation and reperfusion arrhythmias was lower in the ANP group than in the ISDN group. Atrial natriuretic peptide may therefore have cardioprotective effects against reperfusion injury in patients with AMI. Currently, nuclear imaging with 99m Tc-PYP scintigraphy is used to measure the area of initial myocardial damage after AMI (32,33). A significant correlation has been reported between myocardial 99m Tc-PYP scintigraphic uptake and the area at risk in cases of myocardial infarction (34). Because 201 Tl scintigraphic uptake is known to indicate restored myocardial perfusion and cell viability, 201 Tl and 99m Tc-PYP dual SPECT can be useful in identifying the extent of damaged but salvaged myocardium (35). In our study, the ES evaluated by 99m Tc-PYP was similar in both groups. Therefore, the initial area at risk of both groups in this study may be similar. However, defect scores from 201 Tl scintigraphy were significantly lower in the ANP group than in the ISDN group. From this, we concluded that intravenous administration of ANP may increase the amount of salvaged myocardium after reperfusion therapy in patients with AMI. 123 I-meta-iodobenzylguanidine, an analog of the adrenergic neuron blocking agent guanethidine, is thought to use the same mechanism of myocardial uptake and release as norepinephrine (36). An association between myocardial norepinephrine concentration and 123 I-MIBG uptake in patients has been reported previously (37). Therefore, cardiac 123 I-MIBG imaging may be a useful tool for detecting abnormalities of the myocardial adrenergic nervous system in patients with AMI (10). Miura et al. (38) reported that the ischemic preconditioning effect attenuates cardiac sympathetic nerve injury during myocardial isch-
5 JACC Vol. 49, No. 6, 2007 February 13, 2007: Figure 2 Kasama et al. ANP and Cardiac Sympathetic Nerve Activity 671 Representative Single-Photon Emission Computerized Tomographic MIBG Images 3 Weeks After Treatment for Both Groups ANP atrial natriuretic peptide; HLA horizontal long axis; ISDN isosorbide dinitrate; MIBG 123I-meta-Iodobenzylguanidine; SA short axis; VLA vertical long axis.
6 672 Kasama et al. JACC Vol. 49, No. 6, 2007 ANP and Cardiac Sympathetic Nerve Activity February 13, 2007: Figure 3 Representative Anterior Planar Delayed MIBG Images 3 Weeks After Treatment for Both Groups In these 2 examples, delayed heart/mediastinum (H/M) count ratio and washout rate were 2.01 and 36%, respectively, for a patient from group A and 1.55 and 52%, respectively, for a patient from group B. Abbreviations as in Figure 2. emia, suggesting this effect may mediate increasing the myocardial uptake of norepinephrine. However, there are no reports on the changes in cardiac 123 I-MIBG scintigraphic findings in response to ANP administration in patients with AMI. In the present study, the TDS, H/M ratio, and WR determined by cardiac 123 I-MIBG scintigraphy were better in the ANP group than in the ISDN group. Buss et al. (39) reported that aldosterone directly prevents myocardial uptake of norepinephrine in experimental animal model. Moreover, in that study, the mineralocorticoid receptor antagonist spironolactone preserved cardiac norepinephrine uptake in salt-sensitive Dahl rats (39). On the other hand, ANP has been reported to inhibit aldosterone synthase gene expression in cultured neonatal rat cardiocytes (40). Thus, ANP as well as spironolactone may improve cardiac norepinephrine uptake in the failing human heart. Therefore, the present findings demonstrate for the first time that ANP could improve cardiac norepinephrine uptake evaluated by 123 I-MIBG scintigraphy in patients with AMI. In the present study, because a small number of patients were having spironolactone after AMI (2 patients in each group) and the dose of this drug was similar in both groups, it is unlikely that spironolactone influenced our results. Hayashi et al. (9) reported that ANP treatment decreases plasma aldosterone levels and suppresses increasing plasma brain natriuretic peptide (BNP) concentrations after reperfusion therapy in patients with AMI. Plasma aldosterone and BNP levels are well known as predictors of congestive heart failure after myocardial infarction (41,42). Moreover, 123 I-MIBG scintigraphic findings have useful prognostic value in the failing ischemic human heart (10). Therefore, administration of ANP may be effective for the reducing incidence of heart failure after AMI. In the future, we need to evaluate comparative effects of ANP and ISDN on mortality and morbidity in the patients with AMI of this study. Study limitations. The small number of patients with AMI included in this study was a limitation. In addition, the present study used a fixed ANP dose. Future studies must assess the dose-response effects of ANP on 123 I- MIBG scintigraphic findings and LV parameters. In the present study, we did not perform Swan-Ganz catheterization to measure hemodynamic parameters after treatment. However, LVEDP was similar in the 2 groups. We believe that hemodynamic status was similar in the 2 groups and that ANP improves cardiac sympathetic nerve activity in patients with AMI. However, further studies will be required to confirm this hypothesis. It has been reported that intravenous administration of BNP (nesiritide) decreases regional sympathetic nerve activity in patients with coronary heart failure (43). Although nesiritide is used for patients with heart failure in other
7 JACC Vol. 49, No. 6, 2007 February 13, 2007: Kasama et al. ANP and Cardiac Sympathetic Nerve Activity 673 countries, it is not clinically used in Japan. Moreover, cardiac 123 I-MIBG scintigraphy has not yet achieved broad clinical acceptance. Therefore, it is still difficult to compare the effects of intravenous administration of ANP and those of BNP on cardiac sympathetic nerve activity in the failing human heart. We need to evaluate comparative effects of ANP and BNP on cardiac sympathetic nerve activity by cardiac 123 I-MIBG scintigraphy after reperfusion therapy in AMI patients in the future. Recent clinical studies have suggested that stem cell therapy can contribute to the regeneration of infarcted myocardium and enhance neovascularization of ischemic myocardium, resulting in sustained improvement of cardiac function (44,45). However, stem cell therapy is generally expensive for clinical use. Use of ANP is safer, more feasible, and less expensive than stem cell therapy; therefore, we believe that administration of ANP after reperfusion therapy in patients with AMI should be generally applicable. Conclusions. The TDS, H/M ratio, and WR as determined by cardiac 123 I-MIBG scintigraphy were better in the ANP group than in the ISDN group. The ES determined by 99m Tc-PYP was similar in the 2 groups. Two weeks after treatment, LV parameters were better in the ANP group than in the ISDN group. These findings indicate that ANP can benefit cardiac sympathetic nerve activity and LV remodeling in patients with first anterior AMI. Acknowledgments The authors thank Takayoshi Honjo, Akira Nakaya, Hiromitsu Takahashi, Hiroyuki Takada, and Takehiro Ishikawa for their technical assistance. Reprint requests and correspondence: Dr. Shu Kasama, Department of Cardiovascular Medicine, Gunma University School of Medicine, , Showa-machi, Maebashi, Gunma , Japan. s-kasama@bay.wind.ne.jp. REFERENCES 1. Mahmarian JJ, Mahmarian AC, Marks GF, Pratt CM, Verani MS. Role of adenosine thallium-201 tomography for defining long-term risk in patients after acute myocardial infarction. J Am Coll Cardiol 1995;25: Sanz G, Castaner A, Betriu A, et al. Determinants of prognosis in survivors of myocardial infarction: a prospective clinical angiographic study. N Engl J Med 1982;306: White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76: Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol 1978;41: Karlsberg RP, Cryer PE, Roberts R. Serial plasma catecholamine response early in the course of clinical acute myocardial infarction: relationship to infarct extent and mortality. Am Heart J 1981;102: Jugdutt BI, Warnica JW. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct location. Circulation 1988;78: Kosuge M, Miyajima E, Kimura K, Ishikawa T, Tochikubo O, Ishii M. Comparison of atrial natriuretic peptide versus nitroglycerin for reducing blood pressure in acute myocardial infarction. Am J Cardiol 1998;81: Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339: Hayashi M, Tsutamoto T, Wada A, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001;37: Sakata K, Mochizuki M, Yoshida H, et al. Cardiac sympathetic dysfunction contributes to left ventricular remodeling after acute myocardial infarction. Eur J Nucl Med 2000;27: Matsunari I, Schricke U, Bengel FM, et al. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation 2000;101: Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H. ACE inhibition reduces cardiac iodine-123-mibg release in heart failure. J Nucl Med 1997;38: Toyama T, Aihara Y, Iwasaki T, et al. Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting enzyme inhibitor therapy. J Nucl Med 1999;40: Kasama S, Toyama T, Kumakura H, et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 2002;43: Kasama S, Toyama T, Kumakura H, et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003;41: Kasama S, Toyama T, Kumakura H, et al. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med 2003;44: Kasama S, Toyama T, Kumakura H, et al. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity in patients with decompensated congestive heart failure. J Nucl Med 2004;45: Kasama S, Toyama T, Kumakura H, et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol 2005;45: Kasama S, Toyama T, Kumakura H, et al. Effects of perindopril on cardiac sympathetic nerve activity in patients with congestive heart failure: comparison with enalapril. Eur J Nucl Med Mol Imaging 2005;32: Kasama S, Toyama T, Hatori T, et al. Comparative effects of valsartan with enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure. Heart 2006;92: Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis In Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76: Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105: Kasama S, Toyama T, Kumakura H, et al. Effects of nicorandil on cardiac sympathetic nerve activity after reperfusion therapy in patients with first anterior acute myocardial infarction. Eur J Nucl Med Mol Imaging 2005;32: Grines CL, Browne KF, Marco J, et al. Primary Angioplasty in Myocardial Infarction Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328: Lamas GA, Flaker GC, Mitchell G, et al. Survival and Ventricular Enlargement Investigators. Effect of infarct artery patency on prognosis after acute myocardial infarction. Circulation 1995;92: Kloner RA. Does reperfusion injury exist in humans? J Am Coll Cardiol 1993;21: Emori T, Hirata Y, Imai T, Eguchi S, Kanno K, Marumo F. Cellular mechanism of natriuretic peptides-induced inhibition of endothelin-1
8 674 Kasama et al. JACC Vol. 49, No. 6, 2007 ANP and Cardiac Sympathetic Nerve Activity February 13, 2007: biosynthesis in rat endothelial cells. Endocrinology 1993;133: Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74: Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992;70: Okawa H, Horimoto H, Mieno S, Nomura Y, Yoshida M, Shinjiro S. Preischemic infusion of alpha-human atrial natriuretic peptide elicits myoprotective effects against ischemia reperfusion in isolated rat hearts. Mol Cell Biochem 2003;248: Das B, Sarkar C, Karanth KS. Selective mitochondrial K(ATP) channel activation results in antiarrhythmic effect during experimental myocardial ischemia/reperfusion in anesthetized rabbits. Eur J Pharmacol 2002;437: Stokely EM, Buja LM, Lewis SE, et al. Measurement of acute myocardial infarcts in dogs with 99mTc-stannous pyrophosphate scintigrams. J Nucl Med 1976;17: Holman BL, Chisholm RJ, Braunwald E. The prognostic implications of acute myocardial infarct scintigraphy with 99mTc-pyrophosphate. Circulation 1978;57: Koyanagi S, Eastham CL, Harrison DG, Marcus ML. Transmural variation in the relationship between myocardial infarct size and risk area. Am J Physiol 1982;242:H Schofer J, Mathey DG, Montz R, Bleifeld W, Stritzke P. Use of dual intracoronary scintigraphy with thallium-201 and technetium-99m pyrophosphate to predict improvement in left ventricular wall motion immediately after intracoronary thrombolysis in acute myocardial infarction. J Am Coll Cardiol 1983;2: Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med 1980;21: Schofer J, Spielmann R, Schuchert A, Weber K, Schluter M. Iodine- 123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988;12: Miura T, Kawamura S, Tatsuno H, et al. Ischemic preconditioning attenuates cardiac sympathetic nerve injury via ATP-sensitive potassium channels during myocardial ischemia. Circulation 2001;104: Buss SJ, Backs J, Kreusser MM, et al. Spironolactone preserves cardiac norepinephrine reuptake in salt-sensitive Dahl rats. Endocrinology 2006;147: Ito T, Yoshimura M, Nakamura S, et al. Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes. Circulation 2003;107: Hayashi M, Tsutamoto T, Wada A, et al. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 2001;38: Suzuki S, Yoshimura M, Nakayama M, et al. Plasma level of B-type natriuretic peptide as a prognostic marker after acute myocardial infarction: a long-term follow-up analysis. Circulation 2004;110: Brunner-La Rocca HP, Kaye DM, Woods RL, Hastings J, Esler MD. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001;37: Schachinger V, Assmus B, Britten MB, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI trial. J Am Coll Cardiol 2004;44: Assmus B, Schachinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002;106:
Journal of the American College of Cardiology Vol. 45, No. 5, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 45, No. 5, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.11.038
More informationHeart Online First, published on September 13, 2005 as /hrt
Heart Online First, published on September 13, 2005 as 10.1136/hrt.2005.062463 Comparative effects of valsartan with enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide
More informationRelationship between transcardiac gradient of endothelin-1 and left ventricular remodelling in patients with first anterior myocardial infarction
European Heart Journal (2003) 24, 346 355 Relationship between transcardiac gradient of endothelin-1 and left ventricular remodelling in patients with first anterior myocardial infarction T. Tsutamoto
More informationTypical chest pain with normal ECG
Typical chest pain with normal ECG F. Mut, C. Bentancourt, M. Beretta Nuclear Medicine Service, Asociacion Española Montevideo, Uruguay Clinical history Male 41 y.o. Overweight, hypertension, high cholesterol,
More informationJournal of the American College of Cardiology Vol. 38, No. 4, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 38, No. 4, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01477-2 Diabetes
More informationPearls & Pitfalls in nuclear cardiology
Pearls & Pitfalls in nuclear cardiology Maythinee Chantadisai, MD., NM physician Division of Nuclear Medicine, Department of radiology, KCMH Principle of myocardial perfusion imaging (MPI) Radiotracer
More informationCardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.
Complete the following. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. 2. drugs affect the force of contraction and can be either positive or negative. 3.
More informationMethods. Yoshiaki Maruyama, MD; Toru Kato, MD; Hiroyuki Ito, MD; Shugo Tanaka, MD; Nobuo Yoshimoto, MD; Yukio Kishi, MD*; Fujio Numano, MD*
Jpn Circ J 1999; 63: 155 159 New Method of Estimating Myocardial Infarct Size Using Technetium-99m Pyrophosphate and Thallium-201 Dual Single Photon Emission Computed Tomography Imaging Yoshiaki Maruyama,
More information1. LV function and remodeling. 2. Contribution of myocardial ischemia due to CAD, and
1 The clinical syndrome of heart failure in adults is commonly associated with the etiologies of ischemic and non-ischemic dilated cardiomyopathy, hypertrophic cardiomyopathy, hypertensive heart disease,
More informationOTHER NON-CARDIAC USES OF Tc-99m CARDIAC AGENTS Tc-99m Sestamibi for parathyroid imaging, breast tumor imaging, and imaging of other malignant tumors.
DEFINITION OF CARDIAC RADIOPHARMACEUTICAL: A radioactive drug which, when administered for purpose of diagnosis of heart disease, typically elicits no physiological response from the patient. Even though
More informationOUTCOME OF THROMBOLYTIC AND NON- THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION
OUTCOME OF THROMBOLYTIC AND NON- THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION FEROZ MEMON*, LIAQUAT CHEEMA**, NAND LAL RATHI***, RAJ KUMAR***, NAZIR AHMED MEMON**** OBJECTIVE: To compare morbidity,
More informationGated blood pool ventriculography: Is there still a role in myocardial viability?
Gated blood pool ventriculography: Is there still a role in myocardial viability? Oliver C. Alix, MD Adult Clinical and Nuclear Cardiology St. Luke s Medical Centre - Global City Case Presentation A 62-year-old
More informationRecovering Hearts. Saving Lives.
Recovering Hearts. Saving Lives ṬM The Door to Unload (DTU) STEMI Safety & Feasibility Pilot Trial November 218 Recovering Hearts. Saving Lives. LEGAL DISCLAIMERS This presentation includes select slides
More informationVentricular Arrhythmias in Acute MI Patients Undergoing Primary PCI
Ventricular Arrhythmias in Acute MI Patients Undergoing Primary PCI Bulent Gorenek MD FACC FESC Eskişehir Osmangazi University Cardiology Department Eskisehir-Turkey I do not have any potential conflict
More informationIschemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Phy
Ischemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Physician, Professor of Medicine Department of Cardiology,
More informationDynamic 123 I-MIBG SPECT reflects sympathetic nervous integrity and predicts clinical outcome in patients with chronic heart failure
ORIGINAL ARTICLE Annals of Nuclear Medicine Vol. 18, No. 2, 145 150, 2004 Dynamic 123 I-MIBG SPECT reflects sympathetic nervous integrity and predicts clinical outcome in patients with chronic heart failure
More informationInfluence of Treatment Delay on Infarct Size and Clinical Outcome in Patients With Acute Myocardial Infarction Treated With Primary Angioplasty
629 Influence of Treatment Delay on Infarct Size and Clinical Outcome in Patients With Acute Myocardial Infarction Treated With Primary Angioplasty AYLEE L. LIEM, MD, ARNOUD W.J. VAN T HOF, MD, JAN C.A.
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More informationClinical Investigations
Clinical Investigations Deeply Reinverted T Wave at 14 Days After the Onset of First Anterior Acute Myocardial Infarction Predicts Improved Left Ventricular Function at 6 Months Address for correspondence:
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationInnovation therapy in Heart Failure
Innovation therapy in Heart Failure P. Laothavorn September 2015 Topics of discussion Basic Knowledge about heart failure Standard therapy New emerging therapy References: standard Therapy in Heart Failure
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationChapter. Department of Cardiology, 2 Department of Nuclear Medicine and the 3
Chapter 9 Saskia L.M.A. Beeres 1 Jeroen J. Bax 1 Petra Dibbets-Schneider 2 Marcel P.M. Stokkel 2 Willem E. Fibbe 3 Ernst E. van der Wall 1 Martin J. Schalij 1 Douwe E. Atsma 1 1 Department of Cardiology,
More informationVentricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center
Ventricular tachycardia and ischemia Martin Jan Schalij Department of Cardiology Leiden University Medical Center Disclosure: Research grants from: Boston Scientific Medtronic Biotronik Sudden Cardiac
More informationHeart failure and cardiomyopathy
1 Cardiorenal Research Laboratory, Mayo Clinic, Rochester, Minnesota, USA; 2 Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA; 3 Department of Emergency Medicine, Mayo Clinic,
More informationIntraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend )
Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend ) Stephen G. Ellis, MD Section Head, Interventional Cardiology Professor of Medicine Cleveland
More informationJournal of the American College of Cardiology Vol. 39, No. 11, by the American College of Cardiology Foundation ISSN /02/$22.
Journal of the American College of Cardiology Vol. 39, No. 11, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)01856-9
More informationIndex of subjects. effect on ventricular tachycardia 30 treatment with 101, 116 boosterpump 80 Brockenbrough phenomenon 55, 125
145 Index of subjects A accessory pathways 3 amiodarone 4, 5, 6, 23, 30, 97, 102 angina pectoris 4, 24, 1l0, 137, 139, 140 angulation, of cavity 73, 74 aorta aortic flow velocity 2 aortic insufficiency
More informationCardiogenic Shock. Carlos Cafri,, MD
Cardiogenic Shock Carlos Cafri,, MD SHOCK= Inadequate Tissue Mechanisms: Perfusion Inadequate oxygen delivery Release of inflammatory mediators Further microvascular changes, compromised blood flow and
More informationManagement of Acute Myocardial Infarction
Management of Acute Myocardial Infarction Prof. Hossam Kandil Professor of Cardiology Cairo University ST Elevation Acute Myocardial Infarction Aims Of Management Emergency care (Pre-hospital) Early care
More informationComparison with plasma angiotensin II and endothelin-1
European Heart Journal (1999) 2, 1799 187 Article No. euhj.1999.1746, available online at http://www.idealibrary.com on Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality
More informationI have no financial disclosures
Manpreet Singh MD I have no financial disclosures Exercise Treadmill Bicycle Functional capacity assessment Well validated prognostic value Ischemic assessment ECG changes ST segments Arrhythmias Hemodynamic
More informationAbnormal, Autoquant Adenosine Myocardial Perfusion Heart Imaging. ID: GOLD Date: Age: 46 Sex: M John Doe Phone (310)
Background: Reason: preoperative assessment of CAD, Shortness of Breath Symptom: atypical chest pain Risk factors: hypertension Under influence: a beta blocker Medications: digoxin Height: 66 in. Weight:
More informationCardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition
Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition Table of Contents Volume 1 Chapter 1: Cardiovascular Anatomy and Physiology Basic Cardiac
More informationPreprocedural TIMI Flow and Mortality in Patients With Acute Myocardial Infarction Treated by Primary Angioplasty
Journal of the American College of Cardiology Vol. 43, No. 8, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2003.11.042
More informationJournal of the American College of Cardiology Vol. 55, No. 17, by the American College of Cardiology Foundation ISSN /10/$36.
Journal of the American College of Cardiology Vol. 55, No. 17, 21 21 by the American College of Cardiology Foundation ISSN 735-197/1/$36. Published by Elsevier Inc. doi:1.116/j.jacc.29.11.85 CLINICAL TRIALS
More informationEvidence Supporting Post-MI Use of
Addressing the Gap in the Management of Patients After Acute Myocardial Infarction: How Good Is the Evidence Supporting Current Treatment Guidelines? Michael B. Fowler, MB, FRCP Beta-adrenergic blocking
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationPrevious MI with no intervention
Previous MI with no intervention F. Mut, M. Beretta Nuclear Medicine Service, Asociacion Española Montevideo, Uruguay Clinical history Woman 68 y.o. Recent acute MI (3 weeks) with no intervention. Discharged
More informationImpact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction
Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction Masahito Shigekiyo, Kenji Harada, Ayumi Okada, Naho Terada, Hiroyoshi Yoshikawa, Akira Hirono,
More informationEffects of Cilostazol in Patients With Bradycardiac Atrial Fibrillation
J Cardiol 2001 ; 37: 27 33 Effects of Cilostazol in Patients With Bradycardiac Atrial Fibrillation 1 2 1 Masato Kouki KISHIDA, MD WATANABE, MD Abstract Objectives. Cilostazol, an antithrombotic agent,
More informationReversible defect of 123 I-15-(p-iodophenyl)-9-(R,S)-methylpentadecanoic acid indicates residual viability within infarct-related area
ORIGINAL ARTICLE Annals of Nuclear Medicine Vol. 16, No. 3, 183 187, 2002 Reversible defect of 123 I-15-(p-iodophenyl)-9-(R,S)-methylpentadecanoic acid indicates residual viability within infarct-related
More informationST-elevation myocardial infarctions (STEMIs)
Guidelines for Treating STEMI: Case-Based Questions As many as 25% of eligible patients presenting with STEMI do not receive any form of reperfusion therapy. The ACC/AHA guidelines highlight steps to improve
More informationHon-Kan Yip, MD; Chiung-Jen Wu, MD; Morgan Fu, MD; Kuo-Ho Yeh, MD; Teng-Hung Yu, MD; Wei-Chin Hung, MD; and Mien-Cheng Chen, MD
Clinical Features and Outcome of Patients With Direct Percutaneous Coronary Intervention for Acute Myocardial Infarction Resulting From Left Circumflex Artery Occlusion* Hon-Kan Yip, MD; Chiung-Jen Wu,
More informationPRIMARY CORONARY ANGIOPLASTY VERSUS INTRAVENOUS THROMBOLYSIS FOR ACUTE MYOCARDIAL INFARCTION - A COMPARATIVE STUDY AT QUEEN ALIA HEART INSTITUTE
PRIMARY CORONARY ANGIOPLASTY VERSUS INTRAVENOUS THROMBOLYSIS FOR ACUTE MYOCARDIAL INFARCTION - A COMPARATIVE STUDY AT QUEEN ALIA HEART INSTITUTE Walid Sawalha MD, MBBS (Lond), MRCP(UK)* ABSTRACT Objectives:
More informationOutline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies
Outline Pathophysiology: Mat Maurer, MD Irving Assistant Professor of Medicine Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology : Definitions An inability of the
More informationJournal of the American College of Cardiology Vol. 50, No. 11, by the American College of Cardiology Foundation ISSN /07/$32.
Journal of the American College of Cardiology Vol. 50, No. 11, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.05.035
More informationJournal of the American College of Cardiology Vol. 37, No. 2, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01133-5 Coronary
More informationAdvanced Care for Decompensated Heart Failure
Advanced Care for Decompensated Heart Failure Sara Kalantari MD Assistant Professor of Medicine, University of Chicago Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute coronary syndrome(s), anticoagulant therapy in, 706, 707 antiplatelet therapy in, 702 ß-blockers in, 703 cardiac biomarkers in,
More informationAcute Myocardial Infarction
Acute Myocardial Infarction Hafeza Shaikh, DO, FACC, RPVI Lourdes Cardiology Services Asst.Program Director, Cardiology Fellowship Associate Professor, ROWAN-SOM Acute Myocardial Infarction Definition:
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/21543 holds various files of this Leiden University dissertation Author: Dharma, Surya Title: Perspectives in the treatment of cardiovascular disease :
More informationCardiovascular Disorders Lecture 3 Coronar Artery Diseases
Cardiovascular Disorders Lecture 3 Coronar Artery Diseases By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University Coronary Heart Diseases It is the leading cause of death in
More informationPathophysiology: Heart Failure
Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Medicine Outline Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology Heart Failure: Definitions
More informationThe First 12 Hours. ST-Segment Elevation AMI: Introduction. Definitions
ST-Segment Elevation AMI: The First 12 Hours Acute myocardial infarction (AMI) accounts for half of the deaths due to ischemic heart disease and is associated with significant use of resources. Because
More informationRecurrent Thrombosis in a Case of Coronary Ectasia with Large Thrombus Burden Successfully Treated by Adjunctive Warfarin Therapy
Case Report Acta Cardiol Sin 2013;29:462 466 Recurrent Thrombosis in a Case of Coronary Ectasia with Large Thrombus Burden Successfully Treated by Adjunctive Warfarin Therapy Hung-Hao Lee, 1 Tsung-Hsien
More informationDownloaded from ismj.bpums.ac.ir at 22: on Thursday March 7th 2019
- ( ) - ST. :. (No-reflow). ST :.. SPSS. ( / ) :.(P
More informationDetection and Assessment of MI: Use of Imaging Methods. Robert O. Bonow, M.D.
Detection and Assessment of MI: Use of Imaging Methods Robert O. Bonow, M.D. Detection and Assessment of MI: Use of Imaging Methods Robert O. Bonow, M.D. No Relationships to Disclose Expert Consensus Document
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationCardiovascular nuclear imaging employs non-invasive techniques to assess alterations in coronary artery flow, and ventricular function.
National Imaging Associates, Inc. Clinical guidelines CARDIOVASCULAR NUCLEAR MEDICINE -MYOCARDIAL PERFUSION IMAGING -MUGA CPT4 Codes: Refer to pages 6-9 LCD ID Number: L33960 J 15 = KY, OH Responsible
More informationsingle photon emission computed tomography (SPECT). MATERIALS AND METHODS
ORIGINAL ARTICLE Annals of Nuclear Medicine Vol. 16, No. 8, 563 568, 2002 Ischemic memory image in acute myocardial infarction of 123 I-BMIPP after reperfusion therapy: A comparison with 99m Tc-pyrophosphate
More informationA Prognostic Score for Prediction of Cardiac Mortality Risk After Adenosine Stress Myocardial Perfusion Scintigraphy
Journal of the American College of Cardiology Vol. 45, No. 5, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.08.069
More informationCardiovascular nuclear imaging employs non-invasive techniques to assess alterations in coronary artery flow, and ventricular function.
National Imaging Associates, Inc. Clinical guidelines CARDIOVASCULAR NUCLEAR MEDICINE -MYOCARDIAL PERFUSION IMAGING -MUGA Original Date: October 2015 Page 1 of 9 FOR CMS (MEDICARE) MEMBERS ONLY CPT4 Codes:
More informationObjectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009
Objectives Diastolic Heart Failure and Indications for Echocardiography in the Asian Population Damon M. Kwan, MD UCSF Asian Heart & Vascular Symposium 02.07.09 Define diastolic heart failure and differentiate
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationJournal of the American College of Cardiology Vol. 55, No. 20, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 55, No. 20, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.01.014
More informationContrast Induced Nephropathy
Contrast Induced Nephropathy O CIAKI refers to an abrupt deterioration in renal function associated with the administration of iodinated contrast media O CIAKI is characterized by an acute (within 48 hours)
More informationAcute myocardial infarction. Cardiovascular disorders. main/0202_new 02/03/06. Search date August 2004 Nicholas Danchin and Eric Durand
main/0202_new 02/03/06 Acute myocardial infarction Search date August 2004 Nicholas Danchin and Eric Durand QUESTIONS Which treatments improve outcomes in acute myocardial infarction?...4 Which treatments
More informationMaria Angela S. Cruz-Anacleto, MD
Maria Angela S. Cruz-Anacleto, MD 57/Female Menopausal Non-HTN, non-dm Hypothyroid (s/p RAI 1997) Levothyroxine 100 ug OD 5 Months PTA Chest discomfort Stress Echocardiography 5 Months PTA Chest discomfort
More informationDual-Tracer Gated Myocardial Scintigraphy
APPROVED BY: Director of Radiology Page 1 of 7 Dual-Tracer Gated Myocardial Scintigraphy Primary Indications: Evaluation of myocardial perfusion and viability in patients with known or suspected coronary
More informationTopic Page: congestive heart failure
Topic Page: congestive heart failure Definition: congestive heart f ailure from Merriam-Webster's Collegiate(R) Dictionary (1930) : heart failure in which the heart is unable to maintain an adequate circulation
More informationFAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION
Br. J. clin. Pharmac. (1982), 14, 187S-19lS BENEFICIAL EFFECTS OF CAPTOPRIL IN LEFT VENTRICULAR FAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION J.P. BOUNHOURE, J.G. KAYANAKIS, J.M. FAUVEL & J. PUEL Departments
More informationZahid Rahman Khan, MD(USA), MS Diplomate American Board of Nuclear Medicine Consultant t Nuclear Medicine
Zahid Rahman Khan, MD(USA), MS Diplomate American Board of Nuclear Medicine Consultant t Nuclear Medicine i North West Armed Forces Hospital Tabuk, KSA. 1 Introduction Hibernation: Term coined by Rahimtoola
More informationThe PAIN Pathway for the Management of Acute Coronary Syndrome
2 The PAIN Pathway for the Management of Acute Coronary Syndrome Eyal Herzog, Emad Aziz, and Mun K. Hong Acute coronary syndrome (ACS) subsumes a spectrum of clinical entities, ranging from unstable angina
More informationSPECT TRACERS Tl-201, Tc-99m Sestamibi, Tc-99m Tetrofosmin
SPECT TRACERS Tl-201, Tc-99m Sestamibi, Tc-99m Tetrofosmin Elmer Jasper B. Llanes, M.D. Nuclear Cardiology St. Luke s Medical Center Outline Ideal Physiologic Characteristics of MPI radioactive tracers
More informationHeart Failure. Dr. Alia Shatanawi
Heart Failure Dr. Alia Shatanawi Left systolic dysfunction secondary to coronary artery disease is the most common cause, account to 70% of all cases. Heart Failure Heart is unable to pump sufficient blood
More informationA case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD
A case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD NAVAL HOSPITAL OF ATHENS case presentation Female, 81yo Hx: diabetes mellitus, hypertension, chronic anaemia presented
More informationMedicine Dr. Omed Lecture 2 Stable and Unstable Angina
Medicine Dr. Omed Lecture 2 Stable and Unstable Angina Risk stratification in stable angina. High Risk; *post infarct angina, *poor effort tolerance, *ischemia at low workload, *left main or three vessel
More informationEvaluating Clinical Risk and Guiding management with SPECT Imaging
Evaluating Clinical Risk and Guiding management with SPECT Imaging Raffaele Giubbini Chair and Nuclear Medicine Unit University & Spedali Civili Brescia- Italy U.S. Congressional Budget Office. Technological
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationEjection Fraction in Patients With Chronic Heart Failure. Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction
Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction Keith Miller MD Diastolic Heart Failure Risk Factors Common Risk Factors Aging Female gender Obesity Hypertension Diabetes mellitus
More informationRadiologic Assessment of Myocardial Viability
November 2001 Radiologic Assessment of Myocardial Viability Joshua Moss, Harvard Medical School Year III Patient EF 66yo female with a 3-year history of intermittent chest pain previously relieved by sublingual
More informationJournal of the American College of Cardiology Vol. 35, No. 4, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 4, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00643-9 Early
More informationpresenters 2010 Sameh Sabet Ain Shams University
Guidelines for PCI in late STEMI presenters 2010 Sameh Sabet Assistant Professor of Cardiology Ain Shams University 29% of MI patients have STEMI. NRMI 4 (Fourth National Registry of Myocardial Infarction),
More informationNon-commercial use only
Heart International 2011; volume 6:e22 Triple vessel coronary artery disease presenting as a markedly positive stress electrocardiographic test and a negative SPECT-TL scintigram: a case of balanced ischemia
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationMedical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI
Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist physician Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI Outcome objectives of the discussion: At the end of the
More informationDrugs Used in Heart Failure. Assistant Prof. Dr. Najlaa Saadi PhD pharmacology Faculty of Pharmacy University of Philadelphia
Drugs Used in Heart Failure Assistant Prof. Dr. Najlaa Saadi PhD pharmacology Faculty of Pharmacy University of Philadelphia Heart Failure Heart failure (HF), occurs when cardiac output is inadequate to
More informationSingle-Center Experience with 8-year Follow-up 1
Nuclear Medicine Radiology Arend F. L. Schinkel, MD Abdou Elhendy, MD Ron T. van Domburg, PhD Jeroen J. Bax, MD Roelf Valkema, MD Jos R. T. C. Roelandt, MD Don Poldermans, MD Index terms: Heart, abnormalities,
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationAdvances in the Monitoring & Treatment of Heart Failure
Advances in the Monitoring & Treatment of Heart Failure Darrell J. Solet, MD - Cardiologist & Medical Director - Cardiovascular Institute of the South of Morgan City, Louisiana - Clinical Assistant Professor
More informationFacilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients?
Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction Is it beneficial to patients? Seung-Jea Tahk, MD. PhD. Suwon, Korea Facilitated PCI.. background Degree of coronary flow at
More informationSPECT. quantitative gated SPECT (QGS) II. viability RH-2 QGS. Butterworth. 14% 10% 0.43 cycles/cm ( 39: 21 27, 2002) ( )
21 201 Tl SPECT * * * * * * * * SPECT QGS 99m Tc 201 Tl QGS 20 QGS Butterworth Butterworth 0.39 cycles/cm 14% 10% 0.43 cycles/cm ( r = 0.80 r = 0.86 r = 0.80) 201 Tl QGS ( 39: 21 27, 2002) I. quantitative
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationCronicon CARDIOLOGY. N Laredj*, HM Ali Lahmar and L Hammou. Abstract
Cronicon OPEN ACCESS CARDIOLOGY Research Article Persistent Ischemia in Recovery Predicts Mortality after Myocardial Infarction in Patients Undergoing Dobutamine N Laredj*, HM Ali Lahmar and L Hammou Department
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More information